Skip to main content
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Menu
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Perioperative Apalutamide and ADT Reduce Recurrence Risk in High-Risk Prostate Cancer

Perioperative Apalutamide and ADT Reduce Recurrence Risk in High-Risk Prostate Cancer

November 17, 2026 Dr. Michael Lee – Health Editor Health

Clinical data showed that adding apalutamide and androgen-deprivation therapy before and after surgery reduced the risk of recurrence or death by 62% compared with prostatectomy alone in high-risk localized prostate cancer patients, as reported.

    Key Clinical Takeaways:

  • The PROTEUS trial evaluated 6 months of neoadjuvant and adjuvant apalutamide alongside androgen-deprivation therapy in 2,100 patients.
  • Patients with low-tier high-risk disease experience high cure rates with standard monotherapies, showing minimal event-rate differences from added systemic treatments.
  • Selection protocols prioritize higher-volume, high-grade disease to maximize the clinical benefit of perioperative androgen receptor pathway inhibitors.

High-grade cancers impact clinical trial results

Localized prostate cancer spans a wide biological spectrum of aggressiveness and genomic risk, according to Gleave, a distinguished professor in the department of urologic sciences at the University of British Columbia in Vancouver, Canada, who spoke to CancerNetwork. Unless clinical trials include more patients with higher-volume, high-grade cancers, the event rates in lower-tier high-risk subgroups stay too low to show meaningful differences from standard care, Gleave explained to CancerNetwork.

“You have to recognize that localized prostate cancer is a wide spectrum of aggressiveness, histologically as well as genomically, from low to intermediate to high risk,” Gleave told CancerNetwork.

Evaluating perioperative apalutamide and ADT with surgery in prostate cancer — VJOncology

Patients with low-volume Gleason grade group 4 cancer and a prostate-specific antigen level of 8 ng/mL fall into a low-tier high-risk category and do not benefit from the PROTEUS regimen, Gleave told CancerNetwork. In contrast, trials such as PROTEUS and the biomarker-directed Genomic Umbrella Neoadjuvant Study require multiple positive cores with Gleason pattern 4 or 5 and/or a prostate-specific antigen level above 20 ng/mL.

“If a patient has a low-volume Gleason [grade group] 4 cancer with a prostate-specific antigen [PSA] level of 8 [ng/mL], even though he is high risk, he is low-tier high risk and does not benefit from the PROTEUS regimen,” Gleave told CancerNetwork.

Dr Gleave on Selecting Patients for Perioperative Therapy in High-Risk Prostate Cancer
Photo: OncLive

Systemic treatment reduces death or metastasis risk

Gleave said that 70% of control-arm patients undergoing prostatectomy alone relapsed by 3 years, as reported by MedPage Today.

Introducing active systemic treatment aims to induce tumor regression, improve resectability, address subclinical metastases, and delay subsequent metastatic progression, according to MedPage Today. Mary-Ellen Taplin of Dana-Farber Cancer Institute in Boston discussed findings at the European Society for Medical Oncology congress, noting a 51% lower risk of death or metastasis assessed by prostate-specific membrane antigen PET or conventional imaging, according to MedPage Today.

Perioperative Therapy Tops Prostatectomy Alone in High-Risk Prostate Cancer — MedPage Today

“At ASCO 2026 in the plenary, the PROTEUS main study was presented, which was a very large, 2,100-patient study, which looked at the effect of 6 months of neoadjuvant apalutamide and ADT compared to placebo and ADT, followed by prostatectomy,” Taplin told MedPage Today.

Managing adverse events

Adverse effects associated with apalutamide include fatigue, hot flashes, hypertension, and rash, though these are generally managed easily in clinical practice, according to MedPage Today.

Taplin said that the associated rash is immune-mediated rather than an allergic antibiotic-type reaction, allowing patients to continue treatment with a dose reduction or short interruption, as MedPage Today reported. Clinical data also showed no increase in surgical complications when combining the regimen with prostatectomy, as MedPage Today reported.

Alberto Briganti, MD, PhD, on the Proteus substudy in high-risk prostate cancer — Urology Times

“The rash with apalutamide is different than a rash say with antibiotics,” Taplin told MedPage Today. “It’s less of an allergic type rash and more immune-mediated where patients can continue the drug with a dose reduction or a short interruption.”

Curative opportunities in advanced cohorts

Patient selection remains central to integrating surgery and systemic therapy, requiring physicians to identify individuals with elevated recurrence risk who retain an opportunity for curative surgery, according to MedPage Today. Gleave emphasized that surgical judgment dictates whether a patient is an appropriate candidate for resection, noting that systemic therapy does not render an unresectable tumor resectable, according to CancerNetwork.

Perioperative Apalutamide and ADT Reduce Recurrence Risk in High-Risk Prostate Cancer
Photo: MedPage Today

“From a clinical judgment and patient selection perspective, the sweet spot is higher-volume, high-grade disease,” Gleave told CancerNetwork. “However, if you are considering surgery, these patients still have to fall within the clinical judgment of resectability and appropriateness for surgery. You are not going to make somebody who is unresectable resectable with systemic therapy, and that is where surgical judgment comes in.”


Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.

NEJM August 2026 Perioperative Apalutamide in High-Risk Localized Prostate Cancer — A.I.O.

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related reading

  • Autism Brain Activity Varies Widely Among Individuals
  • Anja Weber Discusses Dual Career and Olympic Departure in New Podcast
  • OVHcloud Launches Olala AI to Reduce European Tech Dependence (archyde.com)
  • Pope Leo XIV Cleared for South America Tour After Lung Cancer Surgery (newsdirectory3.com)

Related

Search:

World Today News

World Today News is your trusted source for global journalism — breaking headlines, in-depth analysis, and reporting from around the world.

Quick Links

  • Privacy Policy
  • About Us
  • Accessibility statement
  • California Privacy Notice (CCPA/CPRA)
  • Contact
  • Cookie Policy
  • Disclaimer
  • DMCA Policy
  • Do not sell my info
  • EDITORIAL TEAM
  • Terms & Conditions

Browse by Location

  • GB
  • NZ
  • US

Connect With Us

© 2026 World Today News. All rights reserved. Your trusted global news source directory.
For contact, advertising, copyright, issues email: [email protected]

Privacy Policy Terms of Service